Airway Therapeutics obtient une subvention de 1,9 million de dollars des NIH pour faire avancer l'étude de phase 2b/3 sur le zelpultide alfa dans la prévention de la dysplasie bronchopulmonaire

Phase 2zelpultide alfaPositive

AI Analysis

Summary

Airway Therapeutics received a $1.9 million NIH grant to advance phase 2b/3 clinical development of zelpultide alfa for bronchopulmonary dysplasia prevention, building on positive phase 1b safety and tolerability results.

Clinical Trial Data

Phase

2b/3

Importance:5/10

Sentiment:

0.60

NIH grantnon-dilutive fundingphase 2b/3bronchopulmonary dysplasiaclinical development

Read the original article

Published by PR Newswire Biotech on September 29, 2026 9:24 PM

Read Original